ImmunoGen Announces Webcast of Presentation and Q&A at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

ImmunoGen, a leader in antibody-drug conjugates for cancer treatment, announced that CEO Mark Enyedy will present at the 40th Annual J.P. Morgan Virtual Healthcare Conference. The presentation is set for 9:00 AM ET on January 12, 2022, followed by a Q&A session at 9:20 AM ET. Investors and interested parties can access a live webcast of the event on the company’s website, with a replay available later. ImmunoGen focuses on developing targeted therapies to improve cancer patient outcomes, promoting a mission to 'TARGET A BETTER NOW.'

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference. The presentation is scheduled for 9:00am ET on January 12, 2022.

Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen’s management team for a question-and-answer session at 9:20am ET.

A webcast of the presentation and question-and-answer session will be accessible live through the “Investors & Media” section of the Company’s website, www.immunogen.com; a replay will be available in the same location.

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211229005002/en/

INVESTOR RELATIONS AND MEDIA

ImmunoGen

Courtney O'Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.

FAQ

What is ImmunoGen's stock symbol?

ImmunoGen's stock symbol is IMGN.

When is ImmunoGen presenting at the J.P. Morgan Healthcare Conference?

ImmunoGen will present at 9:00 AM ET on January 12, 2022.

Where can I watch ImmunoGen's presentation?

The presentation can be watched live on ImmunoGen's website under the 'Investors & Media' section.

What is the focus of ImmunoGen's research?

ImmunoGen focuses on developing antibody-drug conjugates to treat cancer.

Who is leading the presentation for ImmunoGen?

The presentation will be led by Mark Enyedy, President and CEO of ImmunoGen.